Assessing Mobile Apps for Adult ADHD

Inclusion Criteria:

• The participant is aged 18-50 years at time of consent

• Fluent in English.

• Available for 2 contiguous months to participate in study, including 3 in-personvisits to the university.

• Able to sit in a regular chair for 30 minutes in a small room for testing.

• Able to use a keyboard with both hands.

• Normal or corrected to normal vision and hearing.

• Have a smart Phone.

• Estimated Intelligence Quotient (IQ) > 80 as assessed by the Wechsler AbbreviatedScale Intelligence (WASI-II) Matrix Reasoning and Vocabulary subtests.

• Meet established Diagnostic and Statistical Manual of Mental Health-Fifth Edition (DSM-5-TR) presentation for ADHD predominantly inattentive or combined subtype withclinically significant levels of impairment, diagnosed by semi-structured clinicalinterview and the Adult ADHD Clinical Diagnostic Scale (ACDS).

Exclusion Criteria:

• History of diagnosis of childhood neurodevelopmental disorder including autismspectrum disorder and dyslexia, other than ADHD or those specifically allowed in theAllowed Disorders section.

• Lifetime history of DSM5 bipolar disorder, psychotic disorder, panic disorder,agoraphobia, obsessive compulsive disorder as assessed with the MINI InternationalNeuropsychiatric Interview (MINI).

• Current DSM5 diagnosis of posttraumatic stress disorder, or Major DepressiveDisorder or Major Depressive Episode via self-report or as assessed with the MINI.

• Current Persistent Depressive Disorder (Dysthymia) or Anxiety Disorder if not onallowed medication that has been at a stable dose for at least 8 weeks (if onallowed medication with stable dose for 8 weeks, then allow).

• Substance or Alcohol Use Disorder rated as moderate or severe, with symptoms ≥ 4, asassessed by the MINI, or self-report of a Substance/Alcohol Use Disorder (allowendorsement of substance or alcohol use that does not meet moderate-severe usedisorder criterion, if clean at visit).

• History of severe sleep disorder, narcolepsy, epilepsy/seizure disorder, braintumor, stroke, TBI, severe concussion resulting in loss of consciousness andhospitalization, serious oxygen deprivation (such as following heart attack, carbonmonoxide poisoning, near drowning or near suffocation), encephalitis, meningitis, orother major neurological disorder.

• History of chronic fatigue syndrome, Long-COVID.

• Other medical or psychiatric conditions that are sufficient to likely compromisecurrent attentional function and assessment in the opinion of the investigator.

• Current ongoing treatment, deemed by the participant and their PCP as indicated forcontinued use during the study, with psychotropics suspected to alter attentionalfunctioning such as antipsychotic medications, sedative hypnotics, mood stabilizers,benzodiazepines, atypical antidepressants, or anticonvulsants (listed in theExcluded Medications List, or in the opinion of the investigator are likely tointerfere with study cognitive assessments).

• Participant is currently considered a suicide risk in the opinion of theInvestigator, has previously made a suicide attempt, or has a prior history of, oris currently demonstrating active suicidal ideation or self-injurious behavior asmeasured by Columbia Suicide Severity Rating Scale at screening.

• Current treatment with guanfacine (due to the unacceptable risks of rapidwithdrawal) and other medications for focus and attention problems such asStrattera, Modafinil, Armodafinil, and Clonidine that require long wash out periods (see Excluded ADHD Medications List).

• Participant plans to initiate during the primary study new concomitant prescriptionmedications that are on the Excluded Medications List.

• Participant plans to initiate during the primary study behavioral therapy ortraining to improve cognition by means of game or app-based cognitive trainings orneurofeedback.